Timothy P. Clackson - Feb 17, 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role
President and CEO, Director
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Stock symbol
THRX
Transactions as of
Feb 17, 2023
Transactions value $
$0
Form type
4
Date filed
2/21/2023, 06:00 AM
Previous filing
Nov 14, 2022
Next filing
Mar 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Award $0 +274K $0.00 274K Feb 17, 2023 Common Stock 274K $11.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 17, 2024 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.